Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Head/Neck,
Phase I
Phase I/II
Adults
Not Available
Not Available
Lockney, Natalie
Local
Vanderbilt University
01-11-2022
Eligibility
21 Years and older
ALL
false
Inclusion Criteria:
Histologically proven cancer of the head and neck cancer
Histologically proven cancer of the head and neck cancer
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Planned primary or adjuvant radiation or chemoradiation therapy
Planned primary or adjuvant radiation or chemoradiation therapy
Willing and able to provide informed consent
Willing and able to provide informed consent
ECOG PS 0-2
ECOG PS 0-2
Age 21 years
Age 21 years
English speaking
English speaking
Exclusion Criteria:
Currently on gabapentin or ketamine
Currently on gabapentin or ketamine
Prior non-tolerance of gabapentin or ketamine
Prior non-tolerance of gabapentin or ketamine
Unable to administer ketamine intranasally due to anatomical restrictions
Unable to administer ketamine intranasally due to anatomical restrictions
History of seizure disorder
History of seizure disorder
History of schizophrenia
History of schizophrenia
History of increased intracranial pressure
History of increased intracranial pressure
Glomerular filtration rate 30 mL/min/1.73 m2
Glomerular filtration rate 30 mL/min/1.73 m2
Histologically proven cancer of the head and neck cancer
Histologically proven cancer of the head and neck cancer
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)
Planned primary or adjuvant radiation or chemoradiation therapy
Planned primary or adjuvant radiation or chemoradiation therapy
Willing and able to provide informed consent
Willing and able to provide informed consent
ECOG PS 0-2
ECOG PS 0-2
Age 21 years
Age 21 years
English speaking
English speaking
Exclusion Criteria:
Currently on gabapentin or ketamine
Currently on gabapentin or ketamine
Prior non-tolerance of gabapentin or ketamine
Prior non-tolerance of gabapentin or ketamine
Unable to administer ketamine intranasally due to anatomical restrictions
Unable to administer ketamine intranasally due to anatomical restrictions
History of seizure disorder
History of seizure disorder
History of schizophrenia
History of schizophrenia
History of increased intracranial pressure
History of increased intracranial pressure
Glomerular filtration rate 30 mL/min/1.73 m2
Glomerular filtration rate 30 mL/min/1.73 m2
